Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conversion Clear all
Completed Phase 3 Interventional

Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery

NCT00125320
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter
Interventions
RSD1235
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Fort Lauderdale, Florida • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 24, 2007 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Conversion To Monotherapy With Lamictal Extended Release Tablets For Treatment Of Partial Epilepsy

NCT00355082
View directory record Official record
Conditions
Epilepsy, Partial
Interventions
lamotrigine, 300 mg/day, lamotrigine, 250 mg/day
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
13 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
67
States / cities
Alabaster, Alabama • Litchfield Park, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2017 · Synced Oct 23, 2026, 9:44 AM EDT
Withdrawn Not applicable Interventional

Myfortic in High MELD Liver Transplantation

NCT01807767
View directory record Official record
Conditions
High Model for End-Stage Liver Disease (MELD) Score
Interventions
Everolimus, Myfortic and Tacrolimus, Myfortic and Tacrolimus
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 23, 2026, 9:44 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

EXercise-induced PhysioLogical Adaptations In Neurological Disorders

NCT07883720
View directory record Official record
Conditions
Epilepsy, Functional Neurological Disorder, Mild Cognitive Impairment, Dementia, Parkinson Disease, Concussion, Brain, Brain Tumor, Healthy
Interventions
Acute Exercise
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 9:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

AT RISK FOR MS - Clinical Conversion of Female Monozygotic Twins Discordant for CIS/MS

NCT00617383
View directory record Official record
Conditions
Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
10 Years to 45 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 9:44 AM EDT
Terminated Phase 3 Interventional Results available

Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE)

NCT01531387
View directory record Official record
Conditions
Sickle Cell Anemia
Interventions
Hydroxyurea
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 10 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection

NCT03762473
View directory record Official record
Conditions
Renal Transplant Infection
Interventions
Study Group, Control Group
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 23, 2026, 9:44 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

NCT01878786
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA)
Drug
Lead sponsor
Matthew Cooper
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Oct 23, 2026, 9:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Activity in People With Functional Movement Disorders

NCT00448084
View directory record Official record
Conditions
Functional Movement Disorders
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Not applicable Interventional Results available

Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.

NCT01936519
View directory record Official record
Conditions
Immunosuppression, Renal Failure
Interventions
Arm A: Everolimus, Calcineurin Inhibitor
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 23, 2026, 9:44 AM EDT
Terminated Not applicable Interventional

A Prospective, Randomized Trial of Early Versus Late Tracheostomy in Trauma Patients With Severe Brain Injury

NCT00292097
View directory record Official record
Conditions
Respiratory Failure, Traumatic Brain Injury
Interventions
Early tracheostomy, Late tracheostomy
Procedure
Lead sponsor
Memorial Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Johnstown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2008 · Synced Oct 23, 2026, 9:44 AM EDT
Active, not recruiting Not applicable Interventional

Tremor Retrainer Software Application for Functional Tremor

NCT06257069
View directory record Official record
Conditions
Functional Movement Disorder, Functional Neurological Disorder, Functional Neurological Symptom Disorder
Interventions
Tremor Retrainer Smartphone Application
Device
Lead sponsor
University of Virginia
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Incidence of COVID-19 Test Conversion in Post-surgical Patients

NCT04392323
View directory record Official record
Conditions
Sars-CoV2
Interventions
COVID-19 PCR and Serology
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Manhasset, New York • New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 23, 2026, 9:44 AM EDT
Completed No phase listed Observational

Assessment of Children With Tic Onset in the Past 6 Months

NCT01177774
View directory record Official record
Conditions
Tourette Syndrome, Tourette's Disorder, Chronic Motor or Vocal Tic Disorder, Transient Tic Disorder, Tic Disorders, Provisional Tic Disorder
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
5 Years to 10 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Oct 23, 2026, 9:44 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Effective Conversion of Individuals at Risk

NCT05112757
View directory record Official record
Conditions
Obstructive Sleep Apnea, Atrial Fibrillation
Interventions
Smartphone application use
Other
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 23, 2026, 9:44 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells

NCT00777400
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
Efalizumab
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

NCT04410198
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease (ESRD)
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Englewood, Colorado • Caldwell, Idaho • Baton Rouge, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients

NCT01544491
View directory record Official record
Conditions
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Interventions
RAD001, MMF
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Year to 18 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 31, 2019 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02892149
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
3,554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
127
States / cities
Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 2 Interventional Results available

A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants

NCT04124705
View directory record Official record
Conditions
Hypothyroidism, Thyroid Disease, Euthyroid, Thyroid Gland, Thyroid Hormones
Interventions
Armour® Thyroid, Levothyroxine
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 75 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Greenbrae, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Phase 4 Interventional Results available

Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients

NCT00866879
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Sirolimus, Demographic Data, Medical History, and Donor Data, Blood Draws for Control Group, Blood Draws for Experimental Group, Donor Blood Draws, Donor Information, Kidney Biopsy
Drug · Other · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 23, 2026, 9:44 AM EDT
Recruiting Not applicable Interventional

Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysms

NCT07019454
View directory record Official record
Conditions
Technical Sucess, Freedom From Type I and III Endoleaks at 12 Months, Freedom From Stent Graft Migration at 12 Months, Freedom From Aortic Aneurysm Enlargement at 12 Months, Freedom From Aortic Aneurysm Rupture or Conversion to Open Repair at 12 Months
Interventions
Physician Modified Endografting
Device
Lead sponsor
Baystate Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 23, 2026, 9:44 AM EDT
Withdrawn Phase 4 Interventional

An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)

NCT01631513
View directory record Official record
Conditions
Pain, Chronic Back Pain, Chronic Low Back Pain, Osteoarthritis Pain In The Hip or Knee
Interventions
Nucynta ER
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Prairie Village, Kansas • Mandeville, Louisiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 23, 2026, 9:44 AM EDT
Completed Not applicable Interventional

Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)

NCT03824197
View directory record Official record
Conditions
Alzheimer Disease, Cerebral Amyloid Angiopathy
Interventions
EVOO, OO
Other
Lead sponsor
Auburn University
Other
Eligibility
55 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 23, 2026, 9:44 AM EDT